Biotechnology
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

$183.8M

Market Cap • 12/26/2024

2021

(3 years)
Founded

2024

IPO

NASDAQ

Listing Exchange
Flag of US

Warren

Headquarters • New Jersey